Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients

Psychopharmacology

Volumn 219, Issue 3, 2012, Pages 727-736

  Koning, Jeroen P ^a,b,f   Vehof, Jelle ^b   Burger, Huibert ^b   Wilffert, Bob ^b,c   Al Hadithy, Asmar ^b,c,d   Alizadeh, Behrooz ^b   Van Harten, Peter N ^a,b,e   Snieder, Harold ^b  

^a Mental Health Organization GGZ Centraal   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antipsychotics; Dopamine; Movement disorders; Pharmacogenetics; Polymorphism; Schizophrenia; Serotonin

Indexed keywords

DOPAMINE RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; SCAVENGER; SEROTONIN RECEPTOR;

ADOLESCENT; ADULT; AKATHISIA; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DRD2 GENE; FEMALE; GENE; GENE FREQUENCY; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; PARKINSONISM; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN DEGRADATION; SINGLE NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MOVEMENT DISORDERS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, DOPAMINE D2; YOUNG ADULT;

EID: 84856671620     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2394-1     Document Type: Article

References (87)

1. K Aberg DE Adkins J Bukszar BT Webb SN Caroff D del Miller J Sebat S Stroup AH Fanous VI Vladimirov JL McClay JA Lieberman PF Sullivan EJ van den Oord 2010 Genomewide association study of movement-related adverse antipsychotic effects Biol Psychiatry 67 279 282 19875103 10.1016/j.biopsych.2009.08.036
2. AF Al Hadithy B Wilffert RE Stewart NM Looman R Bruggeman JR Brouwers GE Matroos J van Os HW Hoek PN van Harten 2008 Pharmacogenetics of parkinsonism, rigidity, rest tremor, and bradykinesia in African-Caribbean inpatients: differences in association with dopamine and serotonin receptors Am J Med Genet B Neuropsychiatr Genet 147B 890 897 18389501 10.1002/ajmg.b.30746 1:CAS:528:DC%2BD1cXhtFOnu7rL
3. AF Al Hadithy SA Ivanova P Pechlivanoglou A Semke O Fedorenko E Kornetova L Ryadovaya JR Brouwers B Wilffert R Bruggeman AJ Loonen 2009 Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia Prog Neuropsychopharmacol Biol Psychiatry 33 475 481 19439249 10.1016/j.pnpbp.2009.01.010 1:CAS:528:DC%2BD1MXjslKksLg%3D
4. AF Al Hadithy SA Ivanova P Pechlivanoglou B Wilffert A Semke O Fedorenko E Kornetova L Ryadovaya JR Brouwers AJ Loonen 2010 Missense polymorphisms in three oxidative-stress enzymes (GSTP1, SOD2, and GPX1) and dyskinesias in Russian psychiatric inpatients from Siberia Hum Psychopharmacol 25 84 91 20041472 10.1002/hup.1087 1:CAS:528:DC%2BC3cXjsFahtLo%3D
5. I Al-Janabi MJ Arranz AI Blakemore PA Saiz MT Susce PE Glaser D Clark J de Leon 2009 Association study of serotonergic gene variants with antipsychotic-induced adverse reactions Psychiatr Genet 19 305 311 19829168 10.1097/YPG.0b013e3283328dcd
6. A Alkelai L Greenbaum A Rigbi K Kanyas B Lerer 2009 Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients Psychopharmacology (Berl) 206 491 499 10.1007/s00213-009-1627-z 1:CAS:528:DC%2BD1MXpvV2ntbY%3D
7. NC Andreasen M Pressler P Nopoulos D Miller BC Ho 2010 Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs Biol Psychiatry 67 255 262 19897178 10.1016/j.biopsych.2009.08. 040 1:CAS:528:DC%2BC3cXnsFWrsA%3D%3D
8. T Arinami M Gao H Hamaguchi M Toru 1997 A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia Hum Mol Genet 6 577 582 9097961 10.1093/hmg/6.4.577 1:CAS:528:DyaK2sXisFOku7Y%3D (Pubitemid 27142107)
9. MJ Arranz J de Leon 2007 Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research Mol Psychiatry 12 707 747 17549063 10.1038/sj.mp.4002009 1:CAS:528:DC%2BD2sXot1Crurc%3D (Pubitemid 47172693)
10. PR Bakker PN van Harten J van Os 2006 Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis Schizophr Res 83 185 192 16513329 10.1016/j.schres.2006.01.010
11. PR Bakker PN van Harten J van Os 2008 Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions Mol Psychiatry 13 544 556 18180754 10.1038/sj.mp.4002142 1:CAS:528:DC%2BD1cXkvVSht78%3D (Pubitemid 351556033)
12. TR Barnes 1989 A rating scale for drug-induced akathisia Br J Psychiatry 154 672 676 2574607 10.1192/bjp.154.5.672 1:STN:280:DyaK3c%2FovFOrtQ%3D%3D (Pubitemid 19154942)
13. JJ Bartko 1991 Measurement and reliability: statistical thinking considerations Schizophr Bull 17 483 489 1947873 1:STN:280: DyaK38%2FlsVentQ%3D%3D
14. A Bertolino L Fazio G Caforio G Blasi A Rampino R Romano A Di Giorgio P Taurisano A Papp J Pinsonneault D Wang M Nardini T Popolizio W Sadee 2009 Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia Brain 132 417 425 18829695 10.1093/brain/awn248
15. Casey DE (1995) Tardive dyskinesia: pathophysiology. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven, New York, pp 1497-1502
16. DE Casey 2004 Pathophysiology of antipsychotic drug-induced movement disorders J Clin Psychiatry 65 Suppl 9 25 28 15189109 1:CAS:528: DC%2BD2cXls1Gmurs%3D
17. MH Chakos JM Alvir MG Woerner A Koreen S Geisler D Mayerhoff S Sobel JM Kane M Borenstein JA Lieberman 1996 Incidence and correlates of tardive dyskinesia in first episode of schizophrenia Arch Gen Psychiatry 53 313 319 8634009 10.1001/archpsyc.1996.01830040049009 1:STN:280:DyaK283hvF2gsw%3D%3D (Pubitemid 26115304)
18. CU Correll EM Schenk 2008 Tardive dyskinesia and new antipsychotics Curr Opin Psychiatry 21 151 156 18332662 10.1097/YCO.0b013e3282f53132 (Pubitemid 351339869)
19. CU Correll S Leucht JM Kane 2004 Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1 year studies Am J Psychiatry 161 414 425 14992963 10.1176/appi.ajp.161.3.414 (Pubitemid 38326094)
20. J de Leon MT Susce RM Pan WH Koch PJ Wedlund 2005 Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness J Clin Psychopharmacol 25 448 456 16160620 10.1097/01.jcp.0000177546.34799.af (Pubitemid 41368367)
21. J Duan MS Wainwright JM Comeron N Saitou AR Sanders J Gelernter PV Gejman 2003 Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor Hum Mol Genet 12 205 216 12554675 10.1093/hmg/ddg055 1:CAS:528:DC%2BD3sXitVWqtr8%3D (Pubitemid 36204418)
22. P Eichhammer M Albus M Borrmann-Hassenbach A Schoeler A Putzhammer U Frick HE Klein T Rohrmeier 2000 Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia Am J Med Genet 96 187 191 10893495 10.1002/(SICI)1096-8628(20000403)96:2<187::AID-AJMG13>3. 0.CO;2-8 1:STN:280:DC%2BD3cvitlyntQ%3D%3D (Pubitemid 30180861)
23. EJ Frackiewicz JJ Sramek JM Herrera NM Kurtz NR Cutler 1997 Ethnicity and antipsychotic response Ann Pharmacother 31 1360 1369 9391692 1:STN:280:DyaK1c%2FltlWrsg%3D%3D (Pubitemid 27498025)
24. J Gerlach 2002 Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria Ann Clin Psychiatry 14 47 57 12046640 (Pubitemid 34538832)
25. WM Glazer 2000 Review of incidence studies of tardive dyskinesia associated with typical antipsychotics J Clin Psychiatry 61 Suppl 4 15 20 10739326 (Pubitemid 30158598)
26. L Greenbaum RD Strous K Kanyas Y Merbl A Horowitz O Karni E Katz M Kotler T Olender SN Deshpande D Lancet E Ben-Asher B Lerer 2007 Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication Pharmacogenet Genomics 17 519 528 17558307 10.1097/FPC. 0b013e32800ffbb4 1:CAS:528:DC%2BD2sXmtlShs7c%3D (Pubitemid 46905218)
27. L Greenbaum RC Smith A Rigbi R Strous O Teltsh K Kanyas M Korner D Lancet E Ben-Asher B Lerer 2009 Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3′-untranslated region Pharmacogenomics J 9 103 110 18347610 10.1038/tpj.2008.6 1:CAS:528:DC%2BD1MXjsVCqu78%3D
28. L Greenbaum A Alkelai A Rigbi Y Kohn B Lerer 2010 Evidence for association of the GLI2 gene with tardive dyskinesia in patients with chronic schizophrenia Mov Disord 25 2809 2817 20939080 10.1002/mds.23377
29. GROUP 2010 Evidence that familial liability for psychosis is expressed as differential sensitivity to cannabis: an analysis of patient-sibling and sibling-control pairs Arch Gen Psychiatry 68 2 138 147
30. A Gunes MG Scordo P Jaanson ML Dahl 2007 Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients Psychopharmacology (Berl) 190 479 484 10.1007/s00213-006-0622-x 1:CAS:528:DC%2BD2sXhtFygs70%3D (Pubitemid 46204465)
31. A Gunes ML Dahl E Spina MG Scordo 2008 Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients Eur J Clin Pharmacol 64 477 482 18205001 10.1007/s00228-007-0450-x 1:CAS:528:DC%2BD1cXjsVCrtLY%3D
32. Guy E (1976) Abnormal Involuntary Movement Scale, ECDEU assessment manual for psychopharmacology. National institute of mental Health, U.S. Department Health and Human Services, National institute of mental Health, U.S. Department Health and Human Services
33. C Guzey MG Scordo E Spina VM Landsem O Spigset 2007 Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms Eur J Clin Pharmacol 63 233 241 17225991 10.1007/s00228-006-0234-8 (Pubitemid 46233150)
34. H Hori O Ohmori T Shinkai H Kojima J Nakamura 2001 Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia Am J Med Genet 105 774 778 11803529 10.1002/ajmg.10045 1:STN:280:DC%2BD38%2FnsVOitA%3D%3D (Pubitemid 33101481)
35. T Inada M Koga H Ishiguro Y Horiuchi A Syu T Yoshio N Takahashi N Ozaki T Arinami 2008 Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia Pharmacogenet Genomics 18 317 323 18334916 10.1097/FPC.0b013e3282f70492 1:CAS:528:DC%2BD1cXjtVKjtbY%3D (Pubitemid 351367525)
36. EG Jonsson MM Nothen F Grunhage L Farde Y Nakashima P Propping GC Sedvall 1999 Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers Mol Psychiatry 4 290 296 10395223 10.1038/sj.mp.4000532 1:CAS:528:DC%2BD3cXlvVWktL0%3D (Pubitemid 29292183)
37. AL Jorgensen PR Williamson 2008 Methodological quality of pharmacogenetic studies: issues of concern Stat Med 27 6547 6569 18837075 10.1002/sim.3420
38. RS Kahn WW Fleischhacker H Boter M Davidson Y Vergouwe IP Keet MD Gheorghe JK Rybakowski S Galderisi J Libiger M Hummer S Dollfus JJ Lopez-Ibor LG Hranov W Gaebel J Peuskens N Lindefors A Riecher-Rossler DE Grobbee 2008 Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial Lancet 371 1085 1097 18374841 10.1016/S0140-6736(08)60486-9 1:CAS:528:DC%2BD1cXktVCns7c%3D (Pubitemid 351418005)
39. R Kaiser PB Tremblay F Klufmoller I Roots J Brockmoller 2002 Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia Mol Psychiatry 7 695 705 12192613 10.1038/sj.mp.4001054 1:CAS:528:DC%2BD38Xmt12qu78%3D (Pubitemid 34984946)
40. JM Kane 2006 Tardive dyskinesia circa 2006 Am J Psychiatry 163 1316 1318 16877639 10.1176/appi.ajp.163.8.1316 (Pubitemid 44464397)
41. JM Kane 2007 Treatment adherence and long-term outcomes CNS Spectr 12 21 26 17934386 (Pubitemid 350099581)
42. JM Kane JM Smith 1982 Tardive dyskinesia: prevalence and risk factors, 1959 to 1979 Arch Gen Psychiatry 39 473 481 6121548 10.1001/archpsyc.1982. 04290040069010 1:STN:280:DyaL387lvFCnsQ%3D%3D (Pubitemid 12152816)
43. JM Kane WW Fleischhacker L Hansen R Perlis A Pikalov 3rd S Assuncao-Talbott 2009 Akathisia: an updated review focusing on second-generation antipsychotics J Clin Psychiatry 70 627 643 19389331 10.4088/JCP.08r04210 1:CAS:528:DC%2BD1MXhsFCltLfE
44. SG Kang HJ Lee JE Choi H An M Rhee L Kim 2009 Association study between glutathione S-transferase GST-M1, GST-T1, and GST-P1 polymorphisms and tardive dyskinesia Hum Psychopharmacol 24 55 60 19051221 10.1002/hup.988 1:CAS:528:DC%2BD1MXisFCgsL0%3D
45. S Kapur D Mamo 2003 Half a century of antipsychotics and still a central role for dopamine D2 receptors Prog Neuropsychopharmacol Biol Psychiatry 27 1081 1090 14642968 10.1016/j.pnpbp.2003.09.004 1:CAS:528:DC%2BD3sXpt1SgtL4%3D (Pubitemid 37464954)
46. S Kapur RB Zipursky G Remington 1999 Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia Am J Psychiatry 156 286 293 9989565 1:STN:280:DyaK1M7kt1Kksw%3D%3D (Pubitemid 29077120)
47. JR Landis GG Koch 1977 The measurement of observer agreement for categorical data Biometrics 33 159 174 843571 10.2307/2529310 1:STN:280:DyaE2s7jsFWqtA%3D%3D (Pubitemid 8054849)
48. M Laruelle 1998 Imaging dopamine transmission in schizophrenia. A review and meta-analysis Q J Nucl Med 42 211 221 9796369 1:STN:280: DyaK1M%2Fht1Clsw%3D%3D (Pubitemid 28529874)
49. Lerer B (2002) Pharmacogenetics of psychotropic drugs. Cambridge University Press, Cambridge
50. B Lerer RH Segman H Fangerau AK Daly VS Basile R Cavallaro HN Aschauer RG McCreadie S Ohlraun N Ferrier M Masellis M Verga J Scharfetter M Rietschel R Lovlie UH Levy HY Meltzer JL Kennedy VM Steen F Macciardi 2002 Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism Neuropsychopharmacology 27 105 119 12062911 10.1016/S0893-133X(02)00293-2 1:CAS:528:DC%2BD38Xktlymt7c%3D (Pubitemid 34626747)
51. JA Lieberman FP Bymaster HY Meltzer AY Deutch GE Duncan CE Marx JR Aprille DS Dwyer XM Li SP Mahadik RS Duman JH Porter JS Modica-Napolitano SS Newton JG Csernansky 2008 Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection Pharmacol Rev 60 358 403 18922967 10.1124/pr.107.00107 1:CAS:528:DC%2BD1MXmsVCht70%3D
52. M Marsalek 2000 Tardive drug-induced extrapyramidal syndromes Pharmacopsychiatry 33 Suppl 1 14 33 11072762 10.1055/s-2000-7672 1:CAS:528:DC%2BD3cXnt1Kmtbc%3D
53. CD Marsden P Jenner 1980 The pathophysiology of extrapyramidal side-effects of neuroleptic drugs Psychol Med 10 55 72 6104342 10.1017/S003329170003960X 1:CAS:528:DyaL3cXhvFSrt7k%3D (Pubitemid 11141134)
54. P Martinez-Martin A Gil-Nagel LM Gracia JB Gomez J Martinez-Sarries F Bermejo 1994 Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group Mov Disord 9 76 83 8139608 10.1002/mds.870090112 1:STN:280:DyaK2c7oslOrtA%3D%3D (Pubitemid 24022618)
55. PS Masand M Roca MS Turner JM Kane 2009 Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review Prim Care Companion J Clin Psychiatry 11 147 154 19750066 10.4088/PCC.08r00612
56. S Miyamoto GE Duncan CE Marx JA Lieberman 2005 Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs Mol Psychiatry 10 79 104 15289815 10.1038/sj.mp.4001556 1:CAS:528:DC%2BD2cXhtFeisL3M (Pubitemid 40139590)
57. H Morgenstern WM Glazer 1993 Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study Arch Gen Psychiatry 50 723 733 8102845 10.1001/archpsyc.1993.01820210057007 1:STN:280:DyaK3szmtlSntw%3D%3D (Pubitemid 23263809)
58. F Ng M Berk O Dean AI Bush 2008 Oxidative stress in psychiatric disorders: evidence base and therapeutic implications Int J Neuropsychopharmacol 11 851 876 18205981 10.1017/S1461145707008401 1:CAS:528:DC%2BD1cXhtVGnsbvN
59. T Pohjalainen K Nagren EK Syvalahti J Hietala 1999 The dopamine D2 receptor 5′-flanking variant,-141C Ins/Del, is not associated with reduced dopamine D2 receptor density in vivo Pharmacogenetics 9 505 509 10780270 1:CAS:528:DyaK1MXmtlGjs7s%3D (Pubitemid 29419569)
60. S Potvin P Blanchet E Stip 2009 Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: a meta-analysis Schizophr Res 113 181 188 19608386 10.1016/j.schres.2009.06.010
61. T Ritchie EP Noble 2003 Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics Neurochem Res 28 73 82 12587665 10.1023/A:1021648128758 1:CAS:528:DC%2BD38XpsFCisrk%3D (Pubitemid 36173228)
62. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W, Davis JM, Leucht S (2011) Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull. doi: 10.1093/schbul/sbq042
63. PS Sachdev 2005 Neuroleptic-induced movement disorders: an overview Psychiatr Clin North Am 28 255 274 15733622 10.1016/j.psc.2004.10.004 (Pubitemid 40279035)
64. NR Schooler JM Kane 1982 Research diagnoses for tardive dyskinesia Arch Gen Psychiatry 39 486 487 6121550 10.1001/archpsyc.1982.04290040080014 1:STN:280:DyaL387lvFCntA%3D%3D (Pubitemid 12152819)
65. JC Schwartz J Diaz C Pilon P Sokoloff 2000 Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions Brain Res Brain Res Rev 31 277 287 10719154 10.1016/S0165-0173(99)00043-0 1:CAS:528:DC%2BD3cXhsleqtrw%3D (Pubitemid 30136182)
66. RH Segman U Heresco-Levy B Finkel R Inbar T Neeman M Schlafman A Dorevitch A Yakir A Lerner T Goltser A Shelevoy B Lerer 2000 Association between the serotonin 2 C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility Psychopharmacology (Berl) 152 408 413 10.1007/s002130000521 1:CAS:528:DC%2BD3MXpvFCq
67. RH Segman U Heresco-Levy B Finkel T Goltser R Shalem M Schlafman A Dorevitch A Yakir D Greenberg A Lerner B Lerer 2001 Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia Mol Psychiatry 6 225 229 11317227 10.1038/sj.mp.4000842 1:CAS:528: DC%2BD3MXhsFGlu7o%3D (Pubitemid 32187875)
68. M Stephens P Donnelly 2003 A comparison of bayesian methods for haplotype reconstruction from population genotype data Am J Hum Genet 73 1162 1169 14574645 10.1086/379378 1:CAS:528:DC%2BD3sXptVGnsL4%3D (Pubitemid 37414228)
69. M Stephens NJ Smith P Donnelly 2001 A new statistical method for haplotype reconstruction from population data Am J Hum Genet 68 978 989 11254454 10.1086/319501 1:STN:280:DC%2BD3M3kslWgsA%3D%3D (Pubitemid 32289743)
70. M Suzuki YL Hurd P Sokoloff JC Schwartz G Sedvall 1998 D3 dopamine receptor mRNA is widely expressed in the human brain Brain Res 779 58 74 9473588 10.1016/S0006-8993(97)01078-0 1:CAS:528:DyaK2sXnvFGlsbk%3D (Pubitemid 28039940)
71. JR Swartz K Burgoyne M Smith R Gadasally J Ananth K Ananth 1997 Tardive dyskinesia and ethnicity: review of the literature Ann Clin Psychiatry 9 53 59 9167836 1:STN:280:DyaK2szhtV2gtQ%3D%3D (Pubitemid 27425019)
72. DE Tenback PN van Harten CJ Slooff J van Os 2006 Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study Am J Psychiatry 163 1438 1440 16877660 10.1176/appi.ajp.163.8.1438 (Pubitemid 44464418)
73. DE Tenback PN van Harten J van Os 2009 Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis Mov Disord 24 16 2309 2315 19645070 10.1002/mds.22707
74. G Tsai DC Goff RW Chang J Flood L Baer JT Coyle 1998 Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia Am J Psychiatry 155 1207 1213 9734544 1:STN:280:DyaK1cvgtlKisQ%3D%3D (Pubitemid 28402514)
75. EJ van den Oord PF Sullivan 2003 False discoveries and models for gene discovery Trends Genet 19 537 542 14550627 10.1016/j.tig.2003.08.003 (Pubitemid 37204912)
76. EJ van den Oord PF Sullivan 2003 A framework for controlling false discovery rates and minimizing the amount of genotyping in the search for disease mutations Hum Hered 56 188 199 15031620 10.1159/000076393 (Pubitemid 38410672)
77. JL Waddington AJ Cross SJ Gamble RC Bourne 1983 Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment Science 220 530 532 6132447 10.1126/science.6132447 1:CAS:528:DyaL3sXhvFWksL0%3D (Pubitemid 13114119)
78. C Waeber JM Palacios 1994 Binding sites for 5-hydroxytryptamine-2 receptor agonists are predominantly located in striosomes in the human basal ganglia Brain Res Mol Brain Res 24 199 209 7968358 10.1016/0169-328X(94)90133-3 1:CAS:528:DyaK2cXkslCgt7s%3D (Pubitemid 24202857)
79. Warrens M (2010) Inequalities between multi-rater kappas. Adv Data Anal Classif: 271-286
80. Weiden P (1994) Neuroleptic-induced parkinsonism. American Psychiatric Association (APA), American Psychiatric Association (APA)
81. PJ Weiden 2007 Understanding and addressing adherence issues in schizophrenia: from theory to practice J Clin Psychiatry 68 Suppl 14 14 19 1:CAS:528:DC%2BD2sXos1Cgsrc%3D
82. B Wilffert AF Al Hadithy VJ Sing G Matroos HW Hoek J van Os R Bruggeman JR Brouwers PN van Harten 2009 The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IX J Psychopharmacol 23 652 659 18562401 10.1177/0269881108091594 1:CAS:528:DC%2BD1MXhtV2iurnM
83. SN Wu R Gao QH Xing HF Li YF Shen NF Gu GY Feng L He 2006 Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients Acta Pharmacol Sin 27 966 970 16867246 10.1111/j.1745-7254.2006.00355.x 1:CAS:528:DC%2BD28XosVKhtLc%3D (Pubitemid 44127903)
84. CC Zai RW Hwang V De Luca DJ Muller N King GC Zai G Remington HY Meltzer JA Lieberman SG Potkin JL Kennedy 2007 Association study of tardive dyskinesia and 12 DRD2 polymorphisms in schizophrenia patients Int J Neuropsychopharmacol 10 639 651 16959057 10.1017/S1461145706007152 1:CAS:528:DC%2BD2sXhtVWqsrvP (Pubitemid 47517514)
85. CC Zai AK Tiwari DJ Muller V de Luca T Shinkai S Shaikh X Ni D Sibony AN Voineskos HY Meltzer JA Lieberman SG Potkin G Remington JL Kennedy 2010 The catechol-O-methyl-transferase gene in tardive dyskinesia World J Biol Psychiatry 11 803 812 20586531 10.3109/15622975.2010.486043
86. DV Zaykin PH Westfall SS Young MA Karnoub MJ Wagner MG Ehm 2002 Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals Hum Hered 53 79 91 12037407 10.1159/000057986 (Pubitemid 34621657)
87. JP Zhang T Lencz AK Malhotra 2010 D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis Am J Psychiatry 167 763 772 20194480 10.1176/appi.ajp.2009.09040598